Reprints
PubMed
CAVEAT LECTOR
MECHANISM OF ACTION OF ANTIBODY TO CAPSULAR POLYSACCHARIDE IN CRYPTOCOCCUS NEOFORMANS INFECTION
Marta Feldmesser1 and Arturo Casadevall1,2
1
Received 1/5/98 Accepted 1/9/98
11. REFERENCES
1. W.G. Powderly: Cryptococcal meningitis and AIDS. Clin Infect Dis 17, 837-842 (1993)
2.. Zuger, A, E. Louie, R.S. Holzman, M.S. Simberkoff, & J.J. Rahal: Cryptococcal disease in patients with the Acquired Immunodeficiency Syndrome. Ann Int Med 104, 234-240 (1986)
3. S.M. Levitz: The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis 13, 1163-1169 (1991)
4. Huffnagle, G.B., J.L. Yates, & M.F. Lipscomb: T cell-mediated immunity in the lung: a Cryptococcus neoformans pulmonary infection model using SCID and athymic nude mice. Infect Immun 59, 1423-1433 (1991)
5. S.M. Levitz: Macrophage-cryptococcus interactions. Macrophage-pathogen interactions", B.S. Zwilling et al., Marcel Dekker,Inc. New York, pp. 533-543 (1994)
6. Lipscomb, M.F., T. Alvarellos, G.B. Toews, R. Tompkins, Z. Evans, G. Koo, & V. Kumar: Role of natural killer cells in resistance to Cryptococcus neoformans infections in mice. Am J Pathol 128, 354-361 (1987)
7. M.L. Littman: Cryptococcosis (Torulosis). Am J Med 27, 976-988 (1959)
8. Lee, S.C., A. Casadevall, & D.W. Dickson: Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis. Am J Pathol 148, 1267-1274 (1996)
9. Diamond, R.D. & J.E. Bennett: Disseminated cryptococcosis in man: decreased lymphocyte transformation in response to Cryptococcus neoformans. J Infect Dis 127, 694-697 (1973)
10. Haugen, R.K. & R.D. Baker: The pulmonary lesions in cryptococcosis with special reference to subpleural nodules. Am J Clin Pathol 24, 1381-1390 (1954)
11. R.D. Baker: The primary pulmonary lymph node complex of cryptococcosis. Am J Clin Pathol 65, 83-92 (1976)
12. Pirofski, L. & A. Casadevall: Cryptococcus neoformans: paradigm for the role of antibody immunity against fungi? Zbl Bakt 284, 475-495 (1996)
13. Dromer, F., P. Yeni, & J. Charreire: Genetic control of the humoral response to cryptococcal capsular polysaccharide in mice. Immunogenetics 28, 417-424 (1988)
14. Hoag, K.A., N.E. Street, G.B. Huffnagle, & M.F. Lipscomb: Early cytokine production in pulmonary Cryptococcus neoformans infections distinguishes susceptible and resistant mice. Am J Respir Cell Mol Biol 13, 487-495 (1995)
15. Hay, R.J. & E. Reiss: Delayed-type hypersensitivity responses in infected mice elicited by cytoplasmic fractions of Cryptococcus neoformans. Infect Immun 22, 72-79 (1978)
16. J.O. Hill: CD4+ T cells cause multinucleated giant cells to form around Cryptococcus neoformans and confine the yeast within the primary site of infection in the respiratory tract. J Exp Med 175, 1685-1695 (1992)
17. Lim, T.S. & J.W. Murphy: Transfer of immunity to cryptococcosis by T-enriched splenic lymphocytes from Cryptococcus neoformans-sensitized mice. Infect Immun 30, 5-11 (1980)
18. Levitz, S.M., M.P. Dupont, & E.H. Smail: Direct activity of human T lymphocytes and natural killer cells against Cryptococcus neoformans. Infect Immun 62, 194-202 (1994)
19. K.M. Aguirre: A role for B cells in resistance to Cryptococcus neoformans in mice. Infect Immun 65, 525-530 (1997)
20. D.P. Monga: Role of macrophages in resistance of mice to experimental cryptococcosis. Infect Immun 32, 975-978 (1981)
21. Bulmer, G.S. & J.R. Tacker: Phagocytosis of Cryptococcus neoformans by alveolar macrophages. Infect Immun 11, 73-79 (1975)
22. Fung, P.Y.S. & J.W. Murphy: In vitro interactions of immune lymphocytes and Cryptococcus neoformans. Infect Immun 36, 1128-1138 (1982)
23. Fromtling, R.A., H.J. Shadomy, & E.S. Jacobson: Decreased virulence in stable, acapsular mutants of Cryptococcus neoformans. Mycopathologia 79, 23-29 (1982)
24. Cherniak, R., E. Reiss, & S.H. Turner: A galactoxylomannan antigen of Cryptococcus neoformans serotype A. Carbohydrate Research 103, 239-250 (1982)
25. Kozel, T.R. & R.P. Mastroianni: Inhibition of phagocytosis by cryptococcal polysaccharide: dissociation of the attachment and ingestion phases of phagocytosis. Infect Immun 14, 62-67 (1976)
26. Kozel, T.R., M.A. Wilson, & J.W. Murphy: Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans. Infect Immun 59, 3101-3110 (1991)
27. Wilson, M.A. & T.R. Kozel: Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans. Infect Immun 60, 754-761 (1992)
28. Diamond, R.D. & N.F. Erickson, III: Chemotaxis of human neutophils and monocytes induced by Cryptococcus neoformans. Infect Immun 38, 380-382 (1982)
29. Lipovsky, M.M., G. Gekker, S. Hu, L.C. Ehrlich, A.I.M. Hoepelman, & P.K. Peterson: Cryptococcal glucuronoxylomannan induces interleukin (IL)-8 production by human microglia but inhibits neutrophil migration toward IL-8. J Infect Dis 177, 260-263 (1998)
30. Dong, Z.M. & J.W. Murphy: Cryptococcal polysaccharides induce L-selectin shedding and Tumor Necrosis Factor receptor loss from the surface of human neutrophils. J Clin Invest 97, 689-698 (1996)
31. R. Blackstock: Cryptococcal capsular polysaccharide utilizes an antigen-presenting cell to induce a T-suppressor cell to secrete TsF. J Med Vet Mycol 34, 19-30 (1996)
32. Fidel, P.L. & J.W. Murphy: Characterization of an in vitro-stimulated, Cryptococcus neoformans-specific second-order suppressor T cell and its precursor. Infect Immun 56, 1267-1272 (1988)
33. Khakpour, F.R. & J.W. Murphy: Characterization of a third-order suppressor T cell (Ts3) induced by cryptococcal antigen(s). Infect Immun 55, 1657-1662 (1987)
34. Mody, C.H. & R.M. Syme: Effect of polysaccharide capsule and methods of preparation on human lymphocyte proliferation in response to Cryptococcus neoformans. Infect Immun 61, 464-469 (1993)
35. Vecchiarelli, A., C. Monari, C. Retini, D. Pietrella, B. Palazzetti, L. Pitzurra, & A. Casadevall: Cryptococcus neoformans differently regulates B7-1 (CD80) and B7-2 (CD886) expression on human monocytes. Eur J Immunol 27, (1997)
36. Pettoello-Mantovani, M., A. Casadevall, P. Smarnworawong, & H. Goldstein: Enhancement of HIV Type 1 infectivity in vitro by capsular polysaccharide of Cryptococcus neoformans and Haemophilus influenzae. AIDS Research and Human Retroviruses 10, 1079-1087 (1994)
37. Pettoello-Mantovani, M., A. Casadevall, T.R. Kollmann, A. Rubinstein, & H. Goldstein: Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans. Lancet 339, 21-23 (1992)
38. Kozel, T.R., W.F. Gulley, & J.J. Cazin: Immune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsiveness. Infect Immun 18, 701-707 (1977)
39. Breen, J.F., I.C. Lee, F.R. Vogel, & H. Friedman: Cryptococcal capsular polysaccharide-induced modulation of murine immune responses. Infect Immun 36, 47-51 (1982)
40. Sundstrom, J.B. & R. Cherniak: The glucuronoxylomannan of Cryptococcus neoformans serotype A is a type 2 T-cell-independent antigen. Infect Immun 60, 4080-4087 (1992)
41. E.E. Evans: The antigenic composition of cryptococcus neoformans I. A serologic classification by means of the capsular and agglutination reactions. J Immunol 64, 423-430 (1950)
42. E.E. Evans: An immunologic comparison of twelve strains of Cryptococcus neoformans (Torula histolytica). Proc Soc Exp Biol Med 71, 644-646 (1949)
43. Wilson, D.E., J.E. Bennett, & J.W. Bailey: Serologic grouping of Cryptococcus neoformans. Proc Soc Exp Biol Med 127, 820-823 (1968)
44. Ikeda, R., T. Shinoda, Y. Fukazawa, & L. Kaufman: Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates. J Clin Microbiol 16, 22-29 (1982)
45. Kozel, T.R. & T.G. McGaw: Opsonization of Cryptococcus neoformans by human immunoglobulin G: role of immunoglobulin G in phagocytosis by macrophages. Infect Immun 25, 255-261 (1979)
46. McGaw, T.G. & T.R. Kozel: Opsonization of Cryptococcus neoformans by human immunoglobulin G: masking of immunoglobulin G by cryptococcal polysaccharide. Infect Immun 25, 262-267 (1979)
47. Kozel, T.R. & J.J. Cazin: Immune response to Cryptococcus neoformans soluble polysaccharide I. Serological assay for antigen and antibody. Infect Immun 5, 35-41 (1972)
48. Dromer, F., P. Aucouturier, J. Clauvel, G. Saimot, & P. Yeni: Cryptococcus neoformans antibody levels in patients with AIDS. Scand J Infect Dis 20, 283-285 (1988)
49. Houpt, D.C., G.S.T. Pfrommer, B.J. Young, T.A. Larson, & T.R. Kozel: Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect Immun 62, 2857-2864 (1994)
50. DeShaw, M. & L.-A. Pirofski: Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals. Clin Exp Immunol 99, 425-432 (1995)
51. Zhang, H., Z. Zhong, & L. Pirofski: Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody. Infect Immun 65, 1158-1164 (1997)
52. Rebers, P.A., S.A. Barker, M. Heidelberger, Z. Dische, & E.E. Evans: Precipitation of the specific polysaccharide of Cryptococcus neoformans A by Types II and XIV antipneumococcal sera. J Amer Chem Soc 80, 1135-1137 (1958)
53. Westerink, M.A.J., D. Amsterdam, R.J. Petell, M.N. Stram, & M.A. Apicella: Septicemia due to DF2 Cause of a false-positive cryptococcal latex agglutination result. Am J Med 83, 155-158 (1987)
54. Melcher, G.P., K.D. Reed, M.G. Rinaldi, J.W. Lee, P.A. Pizzo, & T.J. Walsh: Demonstration of a cell wall antigen cross-reacting with cryptococcal polysaccharide in experimental disseminated trichosporonosis. J Clin Microbiol 29, 192-196 (1991)
55. Levitz, S.M. & A. Tabuni: Binding of Cryptococcus neoformans by human cultured macrophages Requirements for multiple complement receptors and actin. J Clin Invest 87, 528-535 (1991)
56. Zhong, Z. & L. Pirofski: Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies. Infect Immun 64, 3446-3450 (1996)
57. Diamond, R.D. & J.E. Bennett: Prognostic factors in cryptococcal meningitis. Ann Int Med 80, 176-181 (1974)
58. Blumer, S.O. & L. Kaufman: Characterization of immunoglobulin classes of human antibodies to Cryptococcus neoformans. Mycopathologia 61, 55-60 (1977)
59. Bindschadler, D.D. & J.E. Bennett: Serology of human cryptococcosis. Ann Int Med 69, 45-52 (1968)
60. Casadevall, A. & M.D. Scharff: The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies. J Exp Med 174, 151-160 (1991)
61. Feldmesser, M., Y. Kress, & A. Casadevall: Effect of antibody to capsular polysaccharide on eosinophilic pneumonia in murine infection with Cryptococcus neoformans. J Infect Dis (1998) (in press)
62. Goldman, D., S.C. Lee, & A. Casadevall: Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect Immun 62, 4755-4761 (1994)
63. H.H. Gadebusch: Active immunization against Cryptococcus neoformans. J Infect Dis 102, 219-226 (1958)
64. Bergman, F. & K. Stormby: A study of white blood cell and antibody response in mice infected subcutaneously with Cryptococcus neoformans. Sabouraudia 4, 106-111 (1965)
65. Shahar, A., Y. Kletter, & M. Aronson: Granuloma formation in cryptococcosis. Israel J Med Sci 5, 1164-1172 (1969)
66. Gupta, S., M. Ellis, T. Cesario, M. Ruhling, & B. Vayuvegula: Disseminated cryptococcal infection in a patient with hypogammaglobulinemia and normal T cell functions. Am J Med 82, 129-131 (1987)
67. Sarosi, G.A., J.D. Parker, I.L. Doto, & F.E. Tosh: Amphotericin B in cryptococcal meningitis Long-term results of treatment. Ann Int Med 71, 1079-1087 (1969)
68. Iseki, M., M. Anzo, N. Yamashita, & N. Matsuo: Hyper-IgM immunodeficiency with disseminated cryptococcosis. Acta Paediatr 83, 780-782 (1994)
69. Hobbs, M.M., J.R. Perfect, D.L. Granger, & D.T. Durack: Opsonic activity of cerebrospinal fluid in experimental cryptococcal meningitis. Infect Immun 58, 2115-2119 (1990)
70. M.B. Goren: Experimental murine cryptococcosis: effect of hyperimmunization to capsular polysaccharide. J Immunol 98, 914-922 (1967)
71. Monga, D.P., R. Kumar, L.N. Mohapatra, & A.N. Malaviya: Experimental cryptococcosis in normal and B-cell-deficient mice. Infect Immun 26, 1-3 (1979)
72. Perfect, J.R., S.D.R. Lang, & D.T. Durack: Influence of agglutinating antibody in experimental cryptococcal meningitis. Br J Exp Path 62, 595-599 (1981)
73. Shapiro, L.L. & J.B. Neal: Torula meningitis. Arch Neurol Psych 13, 174-190 (1925)
74. Gordon, M.A. & A. Casadevall: Serum therapy for cryptococcal meningitis. Clin Infect Dis 21, 1477-1479 (1995)
75. H.H. Gadebusch: Passive immunization against Cryptococcus neoformans. Proc Soc Exp Biol Med 98, 611-614 (1958)
76. Graybill, J.R. & J. Ahrens: Immunization and complement interaction in host defense against murine Cryptococcosis. Journal of the Reticuloendothelial Society 30, 347-357 (1981)
77. Gadebusch, H.H. & A.G. Johnson: Natural host resistance to infection with Cryptococcus neoformans. J Infect Dis 116, 566-572 (1966)
78. Louria, D.B. & T. Kaminski: Passively-acquired immunity in experimental cryptococcosis. Sabouraudia 4, 80-84 (1965)
79. Casadevall, A., J. Mukherjee, S.J.N. Devi, R. Schneerson, J.B. Robbins, & M.D. Scharff: Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis 165, 1086-1093 (1992)
80. Dromer, F., J. Salamero, A. Contrepois, C. Carbon, & P. Yeni: Production, characterization,and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide. Infect Immun 55, 742-748 (1987)
81. Eckert, T.F. & T.R. Kozel: Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide. Infect Immun 55, 1895-1899 (1987)
82. Pirofski, L., R. Lui, M. DeShaw, A.B. Kressel, & Z. Zhong: Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine. Infect Immun 63, 3005-3014 (1995)
83. Zebedee, S.L., R.K. Koduri, J. Mukherjee, S. Mukherjee, S. Lee, D.F. Sauer, M.D. Scharff, & A. Casadevall: Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. Antimicrob Agents Chemother 38, 1507-1514 (1994)
84. Mukherjee, J., M.D. Scharff, & A. Casadevall: Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun 60, 4534-4541 (1992)
85. Mukherjee, J., A. Casadevall, & M.D. Scharff: Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J Exp Med 177, 1105-1116 (1993)
86. Nussbaum, G., W. Cleare, A. Casadevall, M.D. Scharff, & P. Valadon: Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J Exp Med 185, 685-394 (1997)
87. Mukherjee, J., G. Nussbaum, M.D. Scharff, & A. Casadevall: Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J Exp Med 181, 405-409 (1995)
88. Casadevall, A., M. DeShaw, M. Fan, F. Dromer, T.R. Kozel, & L. Pirofski: Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan. Infect Immun 62, 3864-3872 (1994)
89. Valadon, P., G. Nussbaum, L.F. Boyd, D.H. Margulies, & M.D. Scharff: Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans. J Mol Biol 261, 11-22 (1996)
90. Mukherjee, S., S. Lee, J. Mukherjee, M.D. Scharff, & A. Casadevall: Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect Immun 62, 1079-1088 (1994)
91. Dromer, F., J. Charreire, A. Contrepois, C. Carbon, & P. Yeni: Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun 55, 749-752 (1987)
92. Mukherjee, J., L. Pirofski, M.D. Scharff, & A. Casadevall: Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc Natl Acad Sci USA 90, 3636-3640 (1993)
93. Feldmesser, M. & A. Casadevall: Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. J Immunol 158, 790-799 (1997)
94. Mukherjee, J., L.S. Zuckier, M.D. Scharff, & A. Casadevall: Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob Agents Chemother 38, 580-587 (1994)
95. Dromer, F. & J. Charreire: Improved Amphotericin B activity by a monclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J Infect Dis 163, 1114-1120 (1991)
96. Dromer, F., J. Barbet, J. Bolard, J. Charreire, & P. Yeni: Improvement of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomes. Antimicrob Agents Chemother 34, 2055-2060 (1990)
97. Mukherjee, J., M. Feldmesser, M.D. Scharff, & A. Casadevall: Monoclonal antibodies to Cryptococcus neoformans glucuronoxyolomannan enhance fluconazole efficacy. Antimicrob Agents Chemother 39, 1398-1405 (1995)
98. Feldmesser, M., J. Mukherjee, & A. Casadevall: Combination of 5-flucytosine and capsule-binding monoclonal antibody in the treatment of murine Cryptococcus neoformans infections and in vitro. J Antimicrob Chemother 37, 617-622 (1996)
99. Mukherjee, J., M.D. Scharff, & A. Casadevall: Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains. Infect Immun 63, 3353-3359 (1995)
100. Dromer, F., C. Perronne, J. Barge, J.L. Vilde, & P. Yeni: Role of IgG and complement component C5 in the initial course of experimental cryptococcosis. Clin Exp Immunol 78, 412-417 (1989)
101. van de Moer, A., S.L. Salhi, R. Cherniak, B. Pau, M.L. Garrigues, & J.-M. Bastide: An anti-Cryptococcus neoformans monoclonal antibody directed against galactoxylomannan. Res Immunol 141, 33-42 (1990)
102. Hamilton, A.J., L. Jeavons, P. Hobby, & R.J. Hay: A 34- to 38-kilodalton Cryptococcus neoformans glycoprotein produced as an exoantigen bearing a glycosylated species-specific epitope. Infect Immun 60, 143-149 (1992)
103. Hamilton, A.J. & J. Goodley: Purification of the 115-kilodalton exoantigen of Cryptococcus neoformans and its recognition by immune sera. J Clin Microbiol 31, 335-339 (1993)
104. Spira, G., M. Paizi, S. Mazar, G. Nussbaum, S. Mukherjee, & A. Casadevall: Generation of biologically active anti-Cryptococcus neoformans IgG, IgE and IgA isotype switch variant antibodies by acridine orange mutagenesis. Clin Exp Immunol 105, 436-442 (1996)
105. Yuan, R., A. Casadevall, G. Spira, & M.D. Scharff: Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J Immunol 154, 1810-1816 (1995)
106. Yuan, R., A. Casadevall, J. Oh, & M.D. Scharff: T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc Natl Acad Sci USA 94, 2483-2488 (1997)
107. Mukherjee, S., S.C. Lee, & A. Casadevall: Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect Immun 63, 573-579 (1995)
108. Schlageter, A.M. & T.R. Kozel: Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide. Infect Immun 58, 1914-1918 (1990)
109. Sanford, J.E., D.M. Lupan, A.M. Schlageter, & T.R. Kozel: Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect Immun 58, 1919-1923 (1990)
110. Ravetch, J.V. & J. Kinet: Fc receptors. Annu Rev Immunol 9, 457-492 (1991)
111. Mukherjee, J., W. Cleare, & A. Casadevall: Monoclonal antibody mediated capsular reactions (Quellung) in Cryptococcus neoformans. J Immunol Meth 184, 139-143 (1995)
112. Diamond, R.D., R.K. Root, & J.E. Bennett: Factors influencing killing of Cryptococcus neoformans by human leukocytes in vitro. J Infect Dis 125, 367-376 (1972)
113. Cross, C.E. & G.J. Bancroft: Ingestion of acapsular Cryptococcus neoformans occurs via mannose and beta-glucan receptors, resulting in cytokine production and increased phagocytosis of the encapsulated form. Infect Immun 63, 2604-2611 (1995)
114. Weinberg, P.B., S. Becker, D.L. Granger, & H.S. Koren: Growth inhibition of Cryptococcus neoformans by human alveolar macrophages. Am Rev Respir Dis 136, 1242-1247 (1987)
115. Kitz, D.J., G.S. Kobayashi, G. Medoff, & J.R. Little: Growth inhibition of Cryptococcus neoformans by cloned cultured murine macrophages. Cell Immunol 88, 489-500 (1984)
116. Swenson, F.J. & T.R. Kozel: Phagocytosis of Cryptococcus neoformans by normal and thioglycolate-activated macrophages. Infect Immun 21, 714-720 (1978)
117. Kozel, T.R. & J.L. Follette: Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody. Infect Immun 31, 978-984 (1981)
118. T.R. Kozel: Activation of the complement system by pathogenic fungi. Clin Microbiol Rev 9, 34-46 (1996)
119. Cross, C.E., H.L. Collins, & G.J. Bancroft: CR3-dependent phagocytosis by murine macrophages: different cytokines regulate ingestion of a defined CR3 ligand and complement-opsonized Cryptococcus neoformans. Immunol 91, 289-296 (1997)
120. Kawakami, K., S. Kohno, J. Kadota, M. Tohyama, K. Teruya, N. Kudeken, A. Saito, & K. Hara: T cell-dependent activation of macrophages and enhancement of their phagocytic activity in the lungs of mice inoculated with heat-killed Cryptococcus neoformans: involvement of IFN-gamma and its protective effect against cryptococcal infection. Microbiol Immunol 39, 135-143 (1995)
121. Diamond, R.D. & J.E. Bennett: Growth of Cryptococcus neoformans within human macrophages in vitro. Infect Immun 7, 231-236 (1973)
122. Lee, S.C., Y. Kress, M. Zhao, D.W. Dickson, & A. Casadevall: Cryptococcus neoformans survive and replicate in human microglia. Lab Invest 73, 871-879 (1995)
123. Macher, A.M., J.E. Bennett, J.E. Gadek, & M.M. Frank: Complement depletion in cryptococcal sepsis. J Immunol 120, 1686-1690 (1978)
124. Rhodes, J.C., L.S. Wicker, & W.J. Urba: Genetic control of susceptibility to Cryptococcus neoformans in mice. Infect Immun 29, 494-499 (1980)
125. J.C. Rhodes: Contribution of complement component C5 to the pathogenesis of experimental murine cryptococcosis. Sabouraudia: J Med Vet Mycol 23, 225-234 (1985)
126. Lovchik, J.A. & M.F. Lipscomb: Role for C5 and neutrophils in the pulmonary intravascular clearance of circulating Cryptococcus neoformans. Am J Respir Cell Mol Biol 9, 617-627 (1993)
127. Hiemstra, P.S., P.B. Eisenhauer, S.S.L. Harwig, M.T. van den Barselaar, R. van Furth, & R.I. Lehrer: Antimicrobial proteins of murine macrophages. Infect Immun 61, 3038-3046 (1993)
128. Nathan, C.F. & J.B. Hibbs, Jr. Role of nitric oxide synthesis in macrophage antimicrobial activity. Current Opinion in Immunology 3, 65-70 (1991)
129. Levitz, S.M. & D.J. DiBenedetto: Differential stimulation of murine resident peritoneal cells by selectively opsonized encapsulated and acapsular Cryptococcus neoformans. Infect Immun 56, 2544-2551 (1988)
130. Flesch, I.E.A., G. Schwamberger, & S.H.E. Kaufmann: Fungicidal activity of IFN-gamma-activated macrophages Extracellular killing of Cryptococcus neoformans. J Immunol 142, 3219-3224 (1989)
131. R.D. Diamond: Antibody-dependent killing of Cryptococcus neoformans by human peripheral blood mononuclear cells. Nature 247, 148-150 (1974)
132. Levitz, S.M. & T.P. Farrell: Growth inhibition of Cryptococcus neoformans by cultured human monocytes: role of the capsule, opsonins, the culture surface, and cytokines. Infect Immun 58, 1201-1209 (1990)
133. Vasquez-Torres, A., J. Jones-Carson, & E. Balish: Peroxynitrite contributes to the candidacidal activity of nitric oxide-producing macrophages. Infect Immun 64, 3127-3133 (1996)
134. Naslund, P.K., W.C. Miller, & D.L. Granger: Cryptococcus neoformans fails to induce nitric oxide synthase in primed murine macrophage-like cells. Infect Immun 63, 1298-1304 (1995)
135. Mozaffarian, N., J.W. Berman, & A. Casadevall: Immune complexes increase nitric oxide production by interferon-gamma-stimulated murine macrophage-like J774.16 cells. J Leukoc Biol 57, 657-662 (1995)
136. Mukherjee, S., M. Feldmesser, & A. Casadevall: J774 murine macrophage-like cell interactions with Cryptococcus neoformans in the presence and absence of opsonins. J Infect Dis 173, 1222-1231 (1996)
137. Lee, S.C., Y. Kress, D.W. Dickson, & A. Casadevall: Human microglia mediate anti-Cryptococcus neoformans activity in the presence of specific antibody. J Neuroimmunol 62, 43-52 (1995)
138. Curtis, J.L., G.B. Huffnagle, G. Chen, M.L. Warnock, M.R. Gyetko, R.A. McDonald, & G.B. Toews: Experimental murine pulmonary cryptococcosis Differences in pulmonary inflammation and lymphocyte recruitment induced by two encapsulated strains of Cryptococcus neoformans. Lab Invest 71, 113-126 (1994)
139. Kozel, T.R., G.S.T. Pfrommer, & D. Redelman: Activated neutrophils exhibit enhanced phagocytosis of Cryptococcus neoformans opsonized with normal human serum. Clin Exp Immunol 70, 238-246 (1987)
140. Retini, C., A. Vecchiarelli, C. Monari, C. Tascini, F. Bistoni, & T.R. Kozel: Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect Immun 64, 2897-2903 (1996)
141. Kozel, T.R., B. Highison, & C.J. Stratton: Localization on encapsulated Cryptococcus neoformans of serum components opsonic for phagocytosis by macrophages and neutrophils. Infect Immun 43, 574-579 (1984)
142. Miller, G.P.G. & S. Kohl: Antibody-dependent leukocyte killing of Cryptococcus neoformans. J Immunol 131, 1455-1459 (1983)
143. Zhong, Z. & L. Pirofski: Antifungal activity of a human antiglucuronoxylomannan antibody. Clin Diagn Lab Immunol 5, 58-64 (1998)
144. Feldmesser, M., A. Casadevall, Y. Kress, G. Spira, & A. Orlofsky: Eosinophil-Cryptococcus neoformans interactions in vivo and in vitro. Infect Immun 65, 1899-1907 (1997)
145. Collins, H.L. & G.J. Bancroft: Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses. Infect Immun 59, 3883-3888 (1991)
146. Vecchiarelli, A., M. Dottorini, D. Pietrella, C. Monari, C. Retini, T. Todisco, & F. Bistoni: Role of human alveolar macrophages as antigen-presenting cells in Cryptococcus neoformans. Am J Respir Cell Mol Biol 11, 130-137 (1994)
147. Vecchiarelli, A., C. Retini, A. Casadevall, & F. Bistoni: Monoclonal antibody to Cryptococcus neoformans glucuronoxylomannan enhances antigen presenting capacity of human monocytes. Third International Conference on Cryptococcus & Cryptococcosis 24 (1996)
148. Murphy, J.W. & D.O. McDaniel: In vitro reactivity of natural killer (NK) cells against Cryptococcus neoformans. J Immunol 128, 1577-1583 (1982)
149. Miller, M.F., T.G. Mitchell, W.J. Storkus, & J.R. Dawson: Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody. Infect Immun 58, 639-645 (1990)
150. Nabavi, N. & J.W. Murphy: Antibody-dependent natural killer cell-mediated growth inhibition of Cryptococcus neoformans. Infect Immun 51, 556-562 (1986)
151. Salkowski, C.A.& E. Balish: Cryptococcosis in beige mice: the effect of congenital defects in innate immunity on susceptibility. Can J Microbiol 37, 128-135 (1991)
152. Hirano, A., H.M. Zimmerman, & S. Levine: Fine structure of cerebral fluid accumulation. Arch Neurol 12, 189-196 (1965)
153. Hirano, A., H.M. Zimmerman, & S. Levine: The fine structure of cerebral fluid accumulation. III. Extracellular spread of cryptococcal polysaccharides in the acute stage. Am J Pathol 45, 1-19 (1964)
154. Goldman, D.L., S.C. Lee, & A. Casadevall: Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect Immun 63, 3448-3453 (1995)
155. Griffin, F.M., Jr. Roles of macrophage Fc and C3b receptors in phagocytosis of immunologically coated Cryptococcus neoformans. Proc Natl Acad Sci USA 78, 3853-3857 (1981)
156. Kalina, M., Y. Kletter, & M. Aronson: The interaction of phagocytes and the large-sized parasite Cryptococcus neoformans: cytochemical and ultratructural study. Cell Tiss Res 152, 165-174 (1974)
157. Kalina, M., Y. Kletter, A. Shahar, & M. Aronson: Acid phosphatase release from intact phagocytic cells surrounding a lare-sized parasite (35275). Proc Soc Exp Biol Med 136, 407-410 (1971)
158. Aronson, M. & Y. Kletter: Aspects of the defense against a large-sized parasite, the yeast, Cryptococcus neoformans. Is J Med Sci 132-162 (1973)
159. Schneerson-Porat, S., A. Shahar, & M. Aronson: Formation of histiocyte rings in response to Cryptococcus neoformans infection. J Reticuloendothelial Soc 2, 249-255 (1965)
160. Kawakami, K., M. Tohyama, K. Teruya, N. Kudeken, Q. Xie, & A. Saito: Contribution of interferon-gamma in protecting mice during pulmonary and disseminated infection with Cryptococcus neoformans. FEMS Immunol Med Microbiol 13, 123-130 (1996)
161. Kawakami, K., M. Tohyama, Q. Xie, & A. Saito: IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans. Clin Exp Immunol 104, 208-214 (1996)
162. Huffnagle, G.B., G.B. Toews, M.D. Burdick, M.B. Boyd, K.S. McAllister, R.A. McDonald, S.L. Kunkel, & R.M. Strieter: Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans. J Immunol 157, 4529-4536 (1996)
163. Feldmesser, M. & A. Casadevall: Cytokine response to Cryptococcus neoformans in murine pulmonary infection. Abstracts of the 35th Annual Meeting of the Infectious Diseases Society of America San Francisco,CA, 95 (1997)
164. Vecchiarelli, A., D. Pietrella, M. Dottorini, C. Monari, C. Retini, T. Todisco, & F. Bistoni: Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clin Exp Immunol 98, 217-223 (1994)
165. Levitz, S.M., A. Tabuni, S. Nong, & D.T. Golenbock: Effects of interleukin-10 on human peripheral blood mononuclear cell responses to Cryptococcus neoformans, Candida albicans, and lipopolysaccharide. Infect Immun 64, 945-951 (1996)
166. Vecchiarelli, A., C. Retini, C. Monari, C. Tascini, F. Bistoni, & T.R. Kozel: Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect Immun 64, 2846-2849 (1996)
167. Huffnagle, G.B., R.M. Strieter, L.K. McNeil, R.A. McDonald, M.D. Burdick, S.L. Kunkel, & G.B. Toews: Macrophage inflammatory protein-1a (MIP-1alpha) is required for the efferent phase of pulmonary cell-mediated immunity to a Cryptococcus neoformans infection. J Immunol 159, 318-327 (1997)
168. Han, Y. & J.E. Cutler: Antibody response that protects against disseminated candidiasis. Infect Immun 63, 2714-2719 (1995)
169. Glatman-Freedman, A. & A. Casadevall: Serum therapy for tuberculosis revisited: a reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev (1998)(in press)